In QuotedData’s morning briefing 9 May 2025:

• Syncona Limited has provided an update on portfolio company Autolus Therapeutics (Nasdaq: AUTL), following the biotech’s release of Autolus’s results and operational highlights for the first quarter of 2025. Autolus reported US$9.0m in net product revenue for AUCATZYL®, its lead commercial therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL). The product secured conditional marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) during the quarter – a key regulatory milestone. Elsewhere, Autolus continues to progress its broader pipeline. Preliminary data from the Phase 1 CARLYSLE trial in systemic lupus erythematosus (SLE) have shown early promise. The company is planning to launch a pivotal Phase 2 trial in lupus nephritis, alongside a Phase 1 trial in progressive forms of multiple sclerosis, both expected to commence before the end of 2025.
• On 8 May 2025, Dr Alasdair Nairn, executive director of Global Opportunities Trust (GOT), acquired 25,000 shares in GOT at a price of 288p per share for a total consideration of £72,000.
• HydrogenOne Capital Growth (HGEN), the London-listed fund focused on clean hydrogen investments, has announced that it will publish its first quarter 2025 net asset value (NAV) and portfolio update on Wednesday, 14 May 2025 and that, following the release, Richard Hulf and Dr JJ Traynor, managing partners of HGEN’s investment adviser, will host a live investor presentation via the Investor Meet Company platform at 11am BST on the same day. The session is open to both existing and potential shareholders, with the opportunity to submit questions in advance or during the event. Investors can register for free by at: clicking here and anyone already following HydrogenOne on that platform will be automatically invited.

We also have:

Baker Steel supports strategic investment in Futura Resources

Chelverton UK Dividend Trust repays ZDPs and outlines new dividend policy

Stories you may have missed from yesterday:

Small improvement in ICG Enterprise’s discount but there is a long way to go

European Opportunities launches new tender offer

Chrysalis launches shareholder consultation in face of AVI’s calls for a continuation vote

3i Infrastructure has another good year despite widening discount

Damaging Labour budget holds back BlackRock Smaller Companies